Literature DB >> 10331809

Target site selection for an RNA-cleaving catalytic DNA.

M J Cairns1, T M Hopkins, C Witherington, L Wang, L Q Sun.   

Abstract

A small catalytic DNA, known as the 10-23 DNA enzyme or deoxyribozyme, has been shown to efficiently hydrolyze RNA at purine-pyrimidine (R-Y) junctions in vitro. Although these potentially cleavable junctions are ubiquitous, they are often protected from deoxyribozyme activity by RNA secondary structure. We have developed a multiplex cleavage assay for screening the entire length of a target RNA molecule for deoxyribozyme cleavage sites that are efficient, both in terms of kinetics and accessibility. This strategy allowed us to simultaneously compare the RNA cleaving activity of 80 deoxyribozymes for a model target gene (HPV16 E6), and an additional 60 deoxyribozymes against the rat c-myc target. The human papilloma virus (HPV) target was used primarily to characterize the multiplex system and determine its validity. The c-myc target, coupled with a smooth muscle cell proliferation assay, allowed us to assess the relationship between in vitro cleavage efficiency and c-myc gene suppression in cell culture. The multiplex reaction approach streamlines the process of revealing effective deoxyribozymes in a functional assay and provides accessibility data that may also be applicable to site selection for other hybridization-based agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331809     DOI: 10.1038/8658

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  34 in total

1.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Exponential growth by cross-catalytic cleavage of deoxyribozymogens.

Authors:  Matthew Levy; Andrew D Ellington
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

3.  Prioritized selection of oligodeoxyribonucleotide probes for efficient hybridization to RNA transcripts.

Authors:  Kevin J Luebke; Robert P Balog; Harold R Garner
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

4.  A novel replicating circular DNAzyme.

Authors:  Fei Chen; Ruijian Wang; Zhe Li; Bin Liu; Xiaoping Wang; Yanhong Sun; Dongyun Hao; Jin Zhang
Journal:  Nucleic Acids Res       Date:  2004-04-28       Impact factor: 16.971

5.  Nucleic acid mutation analysis using catalytic DNA.

Authors:  M J Cairns; A King; L Q Sun
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

6.  siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells.

Authors:  XiFu Shang; YaoFei Wang; QiChun Zhao; KeRong Wu; Xu Li; XiaoFeng Ji; Rui He; WenZhi Zhang
Journal:  Mol Cell Biochem       Date:  2012-05       Impact factor: 3.396

7.  Effective inhibition of expression of hepatitis B virus genes by DNAzymes.

Authors:  Jian-Er Wo; Xiao-Ling Wu; Lin-Fu Zhou; Hang-Ping Yao; Li-Wei Chen; Reinhard-H Dennin
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

Review 8.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  Coarse-Grained Brownian Dynamics Simulations of the 10-23 DNAzyme.

Authors:  Martin Kenward; Kevin D Dorfman
Journal:  Biophys J       Date:  2009-11-18       Impact factor: 4.033

10.  Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide.

Authors:  Jingru Meng; Gonghao He; Hui Wang; Min Jia; Xue Ma; Fei Da; Ning Wang; Zheng Hou; Xiaoyan Xue; Mingkai Li; Ying Zhou; Xiaoxing Luo
Journal:  J Antibiot (Tokyo)       Date:  2014-10-01       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.